Twist Bioscience (NASDAQ:TWST) Price Target Raised to $54.00

Twist Bioscience (NASDAQ:TWST) had its target price upped by Scotiabank from $50.00 to $54.00 in a report released on Tuesday,Benzinga reports. The firm currently has a sector outperform rating on the stock.

Other equities research analysts have also issued research reports about the company. Evercore ISI increased their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners increased their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Barclays cut their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. JPMorgan Chase & Co. increased their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Finally, Robert W. Baird increased their price target on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and a consensus price target of $51.78.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $41.89 on Tuesday. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of -11.57 and a beta of 1.78. Twist Bioscience has a one year low of $23.07 and a one year high of $60.90. The business has a fifty day moving average price of $43.93 and a 200-day moving average price of $46.15.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,730 shares of the stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total value of $81,206.20. Following the completion of the transaction, the chief executive officer now owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. This trade represents a 0.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Chess sold 3,600 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $47.26, for a total transaction of $170,136.00. Following the completion of the sale, the director now directly owns 21,641 shares of the company’s stock, valued at approximately $1,022,753.66. The trade was a 14.26 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 98,118 shares of company stock valued at $4,391,151. Insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the company. Silvercrest Asset Management Group LLC lifted its stake in Twist Bioscience by 38.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after purchasing an additional 37,376 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock worth $6,057,000 after acquiring an additional 83,287 shares during the period. Magnetar Financial LLC purchased a new position in shares of Twist Bioscience during the first quarter worth approximately $389,000. Price T Rowe Associates Inc. MD increased its position in shares of Twist Bioscience by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock worth $1,103,000 after acquiring an additional 2,292 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in shares of Twist Bioscience during the second quarter worth approximately $402,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.